Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of gemtuzumab ozogamicin added to reinduction chemotherapy in children and adolescents with relapsed or refractory acute myeloid leukemia
2010-018980-41Phase 3Completed
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Started Sep 2013; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-018980-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018980-41.